secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zivo Bioscience, Inc. (ZIVO)
CIK:        0001101026
Form:       8-K
Filed at:   2022-04-15T23:59:59+00:00
Accession:  0001654954-22-005068
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Zivo Bioscience restates Q3 2021 financials; delays 2021 10-K filing
--------------------------------------------------------------------

- Error in accounting for License Co-Development Participation Agreements; restates net loss for Q3 2021 from -$1.93M to -$1.58M.
- Deferred R&D obligation restated to $1.68M; total current liabilities reduced by $350K.
- Concluded internal controls over financial reporting were ineffective; material weakness disclosed.
- Company expects to file amended 10-Q and 10-K after restatement; filed NT 10-K on March 31, 2022.
- Restatement reduces accumulated deficit by $350K to ~$104.7M as of Sep 30, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1101026/000165495422005068/0001654954-22-005068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1101026/000165495422005068/zivo_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-005068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer